Immune organoids: from tumor modeling to precision oncology

Cancer immunotherapies, particularly immune checkpoint inhibitors, are rapidly becoming standard-of- care for many cancers. The ascendance of immune checkpoint inhibitor treatment and limitations in the accurate prediction of clinical response thereof have provided significant impetus to develop preclinical models that can guide therapeutic intervention. Traditional organoid culture methods that exclusively grow tumor epithelium as patient- derived organoids are under investigation as a personalized platform for drug discovery and for predicting clinical efficacy of chemotherapies and targeted agents. Recently, the patient-derived tumor organoid platform has evolved to contain more complex stromal and immune compartments needed to assess immunotherapeutic efficacy. We review the different methodologies for developing a more holistic patient-derived tumor organoid platform and for modeling the native immune tumor microenvironment.

Automated summary

Cancer immunotherapies, especially immune checkpoint inhibitors, have become the standard treatment for many cancers. However, accurately predicting their clinical efficacy is still a challenge. Researchers are developing preclinical models, including patient-derived tumor organoid platforms, to guide therapeutic intervention and assess the effectiveness of immunotherapies.